Ciambra Evropska unija - slovenščina - EMA (European Medicines Agency)

ciambra

menarini international operations luxembourg s.a. - pemetreksed dinatrijev hemipentahidrat - carcinoma, non-small-cell lung; mesothelioma - antineoplastična sredstva - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra je označen kot monotherapy za vzdrževanje zdravljenje lokalno napredno ali metastatskim non-small cell lung cancer razen pretežno skvamoznih celic histologijo pri bolnikih, katerih bolezen ni napredovala takoj po platinum, ki temelji kemoterapijo. ciambra je označen kot monotherapy na drugi liniji zdravljenja bolnikov z lokalno napredno ali metastatskim non-small cell lung cancer razen pretežno skvamoznih celic histologija.

Sunlenca Evropska unija - slovenščina - EMA (European Medicines Agency)

sunlenca

gilead sciences ireland unlimited company - lenacapavir sodium - okužbe z virusom hiv - antivirusi za sistemsko uporabo - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 in 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 in 5.

CIAMBRA 500 mg prašek za koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ciambra 500 mg prašek za koncentrat za raztopino za infundiranje

menarini international o.l.s.a. - pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 500 mg / 1 viala - pemetreksed

CIAMBRA 100 mg prašek za koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ciambra 100 mg prašek za koncentrat za raztopino za infundiranje

menarini international o.l.s.a. - pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 100 mg / 1 viala - pemetreksed

Talvey Evropska unija - slovenščina - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Zeposia Evropska unija - slovenščina - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod hidroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresivi - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Uplizna Evropska unija - slovenščina - EMA (European Medicines Agency)

uplizna

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunosupresivi - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Enspryng Evropska unija - slovenščina - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresivi - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Bimervax Evropska unija - slovenščina - EMA (European Medicines Agency)

bimervax

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - cepiva - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.